Key facts
- This page summarizes Kenneth Greathouse's Form 4 filing for Zosano Pharma Corp.
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 24 Nov 2021, 16:53.
Kenneth Greathouse - 23 Nov 2021 Form 4 Insider Report for Zosano Pharma Corp
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 23 Nov 2021
- Net transaction value
- -$6,018
- SEC form
- 4
- Accepted by SEC
- 24 Nov 2021, 16:53:41 UTC
- Prior SEC filing
- 14 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steven Lo, Attorney-in-Fact for Kenneth Greathouse
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Kenneth Greathouse filed Form 4 for Zosano Pharma Corp on 24 Nov 2021.
Change
- Previous filing in this sequence was filed on 14 Jun 2021.
- Current net transaction value: -$6,018.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZSAN
transaction
Common Stock
Sale
- Transaction value
- $6,018
- Shares
- -10,000
- Change %
- -19%
- Price
- $0.6018*
- Shares after
- 43,500
- Date
- 23 Nov 2021
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Includes 15,000 restricted stock units